CLINICAL TRIAL RECRUITMENT FOR ABBV-744 STUDY FUNDAMENTALS EXPLAINED

In Phase C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment until eventually condition progression or the participants are not able to tolerate the study drugs.For all move cytometry experiments, 10,000 cells for every replicate ended up analyzed, and